Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around

Description

Summary

Official Title

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

Keywords

Myelodysplastic Syndrome (MDS), MDS, Myelodysplastic Syndrome, Venetoclax, Azacitidine, AZA, Venclexta, Preleukemia, Myelodysplastic Syndromes, Syndrome, Venetoclax + Azacitidine (AZA)

Eligibility

Locations

  • University of California, Los Angeles /ID# 221760
    Los Angeles California 90095 United States
  • Torrance Memorial Physician Network Cancer Care /ID# 222702
    Torrance California 90505-5004 United States
  • Duplicate_Providence Medical Foundation /ID# 222633
    Fullerton California 92835 United States
  • PIH Health Whittier Hospital /ID# 222647
    Whittier California 90602-1006 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
ID
NCT04401748
Phase
Phase 3 Myelodysplastic Syndrome Research Study
Study Type
Interventional
Participants
About 531 people participating
Last Updated